Single-dose and Steady-state Pharmacokinetics of BIA 2-093 and Its Metabolites

Inclusion Criteria: * Male or female subjects aged between 18 and 40 years, inclusive OR male or female subjects aged 65 years or more. * If young, subjects who were within 15% of ideal body weight OR, if elderly, subjects who were within 20% of ideal body weight according to the Metropolitan Life Insurance Table. * Subjects who were healthy as determined by pre-study medical history, physical examination, neurological examination, and 12-lead ECG. * Subjects who had clinical laboratory tests acceptable to the Investigator. * Subjects who were negative for HBsAg, HCVAb and HIV-1 and HIV-2 Ab tests at screening. * Subjects who were negative for alcohol and drugs of abuse at screening. * Subjects who were non-smokers or who smoked less than 10 cigarettes or equivalent per day. * Subjects who were able and willing to give written informed consent. * (If female) She was not of childbearing potential by reason of surgery or menopause or, if of childbearing potential, she used one of the following methods of contraception: double barrier or intrauterine. * (If female and with less than 40 years old) She had a negative pregnancy test at screening. Exclusion Criteria: * Subjects who did not conform to the above inclusion criteria. * Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, connective tissue diseases or disorders. * Subjects who had a clinically relevant surgical history. * Subjects who had a clinically relevant family history. * Subjects who had a history of relevant atopy. * Subjects who had a history of relevant drug hypersensitivity. * Subjects who had a history of alcoholism or drug abuse. * Subjects who consumed more than 14 units of alcohol a week. * Subjects who had a significant infection or known inflammatory process on screening and/or admission. * Subjects who had acute gastrointestinal symptoms at the time of screening and/or admission (e.g., nausea, vomiting, diarrhoea, heartburn). * Subjects who had used drugs within 2 weeks of first dosing. * Subjects who had used any investigational drug and/or participated in any clinical trial within 3 months of their first admission to this study. * Subjects who had previously received BIA 2-093. * Subjects who had donated and/or received any blood or blood products within the previous 2 months prior to screening. * Subjects who were vegetarians, vegans and/or had medical dietary restrictions. * Subjects who could not communicate reliably with the investigator. * Subjects who were unlikely to co-operate with the requirements of the study. * Subjects who were unwilling or unable to give written informed consent. * (If female) She was pregnant or breast-feeding * (If female) She was of childbearing potential and she did not use an authorised effective contraceptive method.